Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oxford Martin School is funding two new research programmes that will harness the power of data and collaboration to advance the field of medicine.

The longevity we enjoy today has brought new problems: a rise in chronic conditions such as diabetes, dementia and heart failure, made more complicated by many patients suffering from multiple conditions. At the same time, while the need for new medicines continues to grow unabated, our costly and inefficient drug discovery systems see less than one per cent of efforts reach the market.

These two new research programmes – the Oxford Martin Programme on Deep Medicine and the Oxford Martin Programme on Affordable Medicine – take radical new approaches to these major global challenges.

Read more (Oxford Martin School website)

Similar stories

Multi-partner 'OpenMind' consortium to develop technology for new generation of neurostimulation devices

General Research

Investigators at the University of Oxford, University of California San Francisco (UCSF), Brown University and the Mayo Clinic have joined forces to develop open-source technology platforms for a new generation of neurostimulation devices that not only provide stimulation to the brain but also sense, record, and stream brain activity.

Why we must expand newborn screening

General Research

Professor Laurent Servais of the Department of Paeditrics writes for the Oxford Science Blog on why it is important that we become much more efficient in the diagnosis of treatable conditions and in the treatment of these diseases.

New method for cost-effective genome-wide DNA methylation analysis

General Research

Ludwig Cancer Research team build on its TAPS method to develop an alternative to costly whole-genome sequencing for the detection of DNA methylation.

Azithromycin not effective against COVID-19, trial confirms

Clinical Trials General Research

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.